Home LiteratureArticle Details
PMID: 23702928 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Nature reviews. Cancer ·Vol. 13 ·No. 6 ·2013-06-00 ·Pages 397-411

Cheung NK, Dyer MA

Abstract

Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained to developing risk-based therapies and, ultimately, improving outcome. In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic.

MeSH Terms
Anaplastic Lymphoma Kinase Animals Cancer Vaccines DNA Helicases/genetics Genomics Humans Immunotherapy Mutation Neural Crest/pathology Neuroblastoma/genetics,immunology,therapy Nuclear Proteins/genetics Receptor Protein-Tyrosine Kinases/genetics Sympathetic Nervous System/growth & development,pathology X-linked Nuclear Protein
Chemicals
Cancer Vaccines Nuclear Proteins Anaplastic Lymphoma Kinase Receptor Protein-Tyrosine Kinases DNA Helicases ATRX protein, human X-linked Nuclear Protein
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Cheung Nai-Kong V
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. cheungn@mskcc.org
Dyer Michael A
References (199)
199 references, click to expand
  1. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
    J Clin Oncol. 2005 Apr 1;23(10):2280-99 PMID: 15800319
  2. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.
    Cancer Immunol Immunother. 2000 Jul;49(4-5):259-66 PMID: 10941909
  3. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Clin Cancer Res. 2003 Nov 1;9(14):5214-20 PMID: 14614001
  4. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    J Clin Oncol. 2000 Jan;18(2):376-84 PMID: 10637253
  5. Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma.
    Blood. 2011 Jun 23;117(25):6952-62 PMID: 21521781
  6. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro.
    J Natl Cancer Inst. 1982 Apr;68(4):589-96 PMID: 7040765
  7. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors.
    Semin Nucl Med. 2012 May;42(3):171-84 PMID: 22475426
  8. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Cancer Immunol Immunother. 2011 Sep;60(9):1299-307 PMID: 21626030
  9. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
    J Clin Invest. 2012 Sep;122(9):3260-70 PMID: 22863621
  10. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.
    J Clin Invest. 1996 Dec 15;98(12):2801-4 PMID: 8981927
  11. Identification of ALK as a major familial neuroblastoma predisposition gene.
    Nature. 2008 Oct 16;455(7215):930-5 PMID: 18724359
  12. Accumulation of segmental alterations determines progression in neuroblastoma.
    J Clin Oncol. 2010 Jul 1;28(19):3122-30 PMID: 20516441
  13. Vesicular neurotransmitter transporters: from bacteria to humans.
    Physiol Rev. 1995 Apr;75(2):369-92 PMID: 7724667
  14. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
    Sci Transl Med. 2012 Jan 4;4(115):115ra3 PMID: 22218692
  15. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Clin Cancer Res. 2002 May;8(5):1217-23 PMID: 12006541
  16. Use of NK cell activity in cure by transplant.
    Br J Haematol. 2011 Oct;155(1):14-29 PMID: 21812770
  17. Leaky catecholamine stores: undue waste or a stress response coping mechanism?
    Ann N Y Acad Sci. 2004 Jun;1018:224-30 PMID: 15240373
  18. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    J Clin Invest. 1988 Apr;81(4):1122-8 PMID: 2450893
  19. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
    Nat Genet. 2012 Oct;44(10):1126-30 PMID: 22941191
  20. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    N Engl J Med. 1999 Jun 24;340(25):1954-61 PMID: 10379019
  21. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
    J Natl Cancer Inst. 2006 Sep 6;98(17):1193-203 PMID: 16954472
  22. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
    J Clin Oncol. 2011 Mar 20;29(9):1168-74 PMID: 21343563
  23. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.
    Cancer Res. 2001 Jan 1;61(1):363-9 PMID: 11196188
  24. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth.
    J Cell Sci. 2004 Jul 1;117(Pt 15):3319-29 PMID: 15226403
  25. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
    Int J Cancer. 2012 Oct 1;131(7):1591-600 PMID: 22234802
  26. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
    Cancer Chemother Pharmacol. 2011 Nov;68(5):1291-304 PMID: 21448591
  27. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma.
    Eur J Cancer. 2009 Nov;45(16):2915-21 PMID: 19695868
  28. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  29. Bilateral adrenal neuroblastoma.
    Pediatr Blood Cancer. 2009 Feb;52(2):196-202 PMID: 18951434
  30. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
    J Clin Oncol. 2009 Jan 10;27(2):289-97 PMID: 19047291
  31. Therapeutic intervention with complement and beta-glucan in cancer.
    Immunopharmacology. 1999 May;42(1-3):61-74 PMID: 10408367
  32. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
    Nat Med. 2008 Nov;14(11):1264-70 PMID: 18978797
  33. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
    Cancer Res. 2001 May 1;61(9):3591-4 PMID: 11325825
  34. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.
    Science. 1984 Jun 8;224(4653):1121-4 PMID: 6719137
  35. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
    Epigenetics. 2011 Aug;6(8):962-70 PMID: 21725203
  36. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.
    Cancer Treat Rev. 2007 Aug;33(5):484-96 PMID: 17562357
  37. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Cancer Discov. 2013 Mar;3(3):308-23 PMID: 23430699
  38. Survivin minigene DNA vaccination is effective against neuroblastoma.
    Int J Cancer. 2009 Jul 1;125(1):104-14 PMID: 19291796
  39. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
    Nat Immun. 1998;16(5-6):263-74 PMID: 11061594
  40. Humanized mice in translational biomedical research.
    Nat Rev Immunol. 2007 Feb;7(2):118-30 PMID: 17259968
  41. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
    Clin Cancer Res. 2010 Aug 1;16(15):3901-9 PMID: 20542985
  42. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells.
    ASN Neuro. 2011 Apr 07;3(2): PMID: 21395555
  43. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
    Sci Transl Med. 2012 Jul 4;4(141):141ra91 PMID: 22764207
  44. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
    PLoS One. 2012;7(1):e30264 PMID: 22279576
  45. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma.
    N Engl J Med. 1984 Jul 26;311(4):231-5 PMID: 6738617
  46. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):975-8 PMID: 18923525
  47. The L1 cell adhesion molecule as a target for radioimmunotherapy.
    Cancer Biother Radiopharm. 2007 Apr;22(2):175-84 PMID: 17600464
  48. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
    Cancer Res. 2010 Dec 1;70(23):9554-61 PMID: 20935224
  49. Oncogenic mutations of ALK kinase in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):971-4 PMID: 18923524
  50. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
    BMC Cancer. 2009 Nov 25;9:411 PMID: 19939254
  51. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Cancer Cell. 2012 Jul 10;22(1):117-30 PMID: 22789543
  52. Neuroblastoma in adolescents: the Italian experience.
    Cancer. 2006 Mar 15;106(6):1409-17 PMID: 16475209
  53. Persistent expression of BMP-4 in embryonic chick adrenal cortical cells and its role in chromaffin cell development.
    Neural Dev. 2008 Oct 22;3:28 PMID: 18945349
  54. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
    N Engl J Med. 2008 Jun 12;358(24):2585-93 PMID: 18463370
  55. The genetic landscape of high-risk neuroblastoma.
    Nat Genet. 2013 Mar;45(3):279-84 PMID: 23334666
  56. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
    Lancet Oncol. 2008 Mar;9(3):247-56 PMID: 18308250
  57. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
    Nat Genet. 2013 Jan;45(1):12-7 PMID: 23202128
  58. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
    Curr Cancer Drug Targets. 2009 Sep;9(6):729-37 PMID: 19754357
  59. The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A.
    Int J Oncol. 2009 Mar;34(3):697-705 PMID: 19212675
  60. Neuroblastoma genetics and phenotype: a tale of heterogeneity.
    Semin Cancer Biol. 2011 Oct;21(4):238-44 PMID: 21839839
  61. A novel retinoblastoma therapy from genomic and epigenetic analyses.
    Nature. 2012 Jan 11;481(7381):329-34 PMID: 22237022
  62. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Clin Cancer Res. 2004 Jul 15;10(14):4839-47 PMID: 15269160
  63. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
    Cancer Res. 2000 Jun 1;60(11):3013-8 PMID: 10850450
  64. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.
    J Clin Invest. 1990 Dec;86(6):1806-14 PMID: 2174908
  65. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
    Cancer Res. 2002 Nov 15;62(22):6651-8 PMID: 12438263
  66. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma.
    Oncogene. 2004 May 20;23(23):4146-54 PMID: 15064733
  67. Mechanisms of immune evasion of human neuroblastoma.
    Cancer Lett. 2005 Oct 18;228(1-2):155-61 PMID: 15923080
  68. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans.
    Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):658-63 PMID: 22328350
  69. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
    Invest New Drugs. 2012 Feb;30(1):191-9 PMID: 20890785
  70. Trk receptor expression and inhibition in neuroblastomas.
    Clin Cancer Res. 2009 May 15;15(10):3244-50 PMID: 19417027
  71. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Blood. 2002 Jun 1;99(11):4166-73 PMID: 12010822
  72. Mutation and cancer: neuroblastoma and pheochromocytoma.
    Am J Hum Genet. 1972 Sep;24(5):514-32 PMID: 4340974
  73. Targeting natural killer cells and natural killer T cells in cancer.
    Nat Rev Immunol. 2012 Mar 22;12(4):239-52 PMID: 22437937
  74. Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression.
    J Clin Invest. 2012 Sep;122(9):3145-58 PMID: 22922260
  75. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study.
    Int J Oncol. 1993 Nov;3(5):909-15 PMID: 21573452
  76. Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction.
    Hum Mol Genet. 2005 Dec 1;14(23):3697-708 PMID: 16249188
  77. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
    Clin Cancer Res. 1998 Sep;4(9):2135-9 PMID: 9748131
  78. VCN-releasable sialic acid and gangliosides in human neuroblastomas.
    J Pediatr Surg. 1977 Jun;12(3):413-8 PMID: 874729
  79. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
    Clin Cancer Res. 2009 Dec 1;15(23):7330-4 PMID: 19934297
  80. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci.
    PLoS Genet. 2011 Mar;7(3):e1002026 PMID: 21436895
  81. Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo.
    Clin Cancer Res. 2009 Nov 1;15(21):6602-8 PMID: 19825945
  82. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.
    Mol Cancer Ther. 2009 Aug;8(8):2392-401 PMID: 19671753
  83. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    J Clin Oncol. 2012 Sep 10;30(26):3264-70 PMID: 22869886
  84. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
    Cancer Res. 2012 Apr 15;72(8):2068-78 PMID: 22350409
  85. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.
    Clin Cancer Res. 2009 Sep 1;15(17):5323-37 PMID: 19723653
  86. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Neoplasia. 2004 Sep-Oct;6(5):558-68 PMID: 15548365
  87. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
    Nat Rev Clin Oncol. 2012 May 15;9(7):391-9 PMID: 22585002
  88. Identification of tumoral glial precursor cells in neuroblastoma.
    Cancer Lett. 2011 Dec 15;312(1):73-81 PMID: 21903323
  89. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
    Mol Oncol. 2008 Oct;2(3):261-71 PMID: 19383347
  90. Anti-GD2 antibody therapy for GD2-expressing tumors.
    Curr Cancer Drug Targets. 2010 Mar;10(2):200-9 PMID: 20201786
  91. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    J Clin Oncol. 2006 Jun 20;24(18):2885-90 PMID: 16682723
  92. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.
    Oncoimmunology. 2012 Jul 1;1(4):477-486 PMID: 22754766
  93. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
    Nature. 2011 Jan 13;469(7329):216-20 PMID: 21124317
  94. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.
    J Immunol. 2012 Sep 1;189(5):2656-64 PMID: 22844125
  95. Therapeutic targeting of miRNAs in neuroblastoma.
    Expert Opin Ther Targets. 2010 Sep;14(9):951-62 PMID: 20658962
  96. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.
    Nat Genet. 2012 Nov;44(11):1199-206 PMID: 23042116
  97. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
    Cancer Res. 2009 Aug 1;69(15):6275-81 PMID: 19584290
  98. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.
    Cancer Res. 2001 May 15;61(10):4048-54 PMID: 11358824
  99. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
    Oncogene. 1997 Jan 30;14(4):439-49 PMID: 9053841
  100. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma.
    Cancer Res. 2012 May 15;72(10):2565-77 PMID: 22589275
  101. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Mol Cancer Ther. 2011 Nov;10(11):2115-23 PMID: 21885865
  102. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57 PMID: 16912267
  103. Preclinical models for neuroblastoma: establishing a baseline for treatment.
    PLoS One. 2011 Apr 29;6(4):e19133 PMID: 21559450
  104. Can the exome and the immunome converge on the design of efficient cancer vaccines?
    Oncoimmunology. 2012 Aug 1;1(5):579-580 PMID: 22934249
  105. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.
    Mol Ther. 2010 Nov;18(11):2006-17 PMID: 20842106
  106. Antibody markers identify a common progenitor to sympathetic neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympathoadrenal lineage.
    J Neurosci. 1991 Nov;11(11):3507-19 PMID: 1941094
  107. Telomeres and telomerase: the means to the end (Nobel lecture).
    Angew Chem Int Ed Engl. 2010 Oct 4;49(41):7405-21 PMID: 20821774
  108. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
    Cancer Cell. 2011 Sep 13;20(3):384-99 PMID: 21907928
  109. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays.
    J Exp Med. 1989 Aug 1;170(2):511-26 PMID: 2526848
  110. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
    J Pediatr Surg. 2009 Dec;44(12):2258-66 PMID: 20006006
  111. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
    Cancer Cell. 2012 Mar 20;21(3):362-73 PMID: 22439933
  112. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
    Blood. 1992 Mar 15;79(6):1484-90 PMID: 1347707
  113. Characterization and IL-15 dependence of NK cells in humanized mice.
    Immunobiology. 2011 Jan-Feb;216(1-2):218-24 PMID: 20627447
  114. Massive genomic rearrangement acquired in a single catastrophic event during cancer development.
    Cell. 2011 Jan 7;144(1):27-40 PMID: 21215367
  115. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues.
    J Clin Oncol. 2000 Jul;18(13):2582-92 PMID: 10893290
  116. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.
    Curr Pharm Des. 2009;15(4):424-9 PMID: 19199969
  117. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.
    Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4498-503 PMID: 8633097
  118. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):967-70 PMID: 18923523
  119. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
    J Clin Invest. 2012 Jun;122(6):2221-33 PMID: 22565311
  120. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway.
    J Biol Chem. 2001 Mar 23;276(12):9526-31 PMID: 11121404
  121. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen.
    J Cell Biol. 1993 Jan;120(2):545-56 PMID: 7678422
  122. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
    J Clin Invest. 2009 Jun;119(6):1524-36 PMID: 19411762
  123. Neuroblastoma: issues in transplantation.
    Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S92-100 PMID: 22226119
  124. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
    J Clin Oncol. 2010 Nov 20;28(33):4969-75 PMID: 20921469
  125. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
    Nature. 2012 Feb 22;483(7391):589-93 PMID: 22367537
  126. Epitope landscape in breast and colorectal cancer.
    Cancer Res. 2008 Feb 1;68(3):889-92 PMID: 18245491
  127. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
    J Neurooncol. 2010 May;97(3):409-18 PMID: 19890606
  128. Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.
    PLoS One. 2012;7(1):e29922 PMID: 22253825
  129. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
    J Immunother. 2010 Oct;33(8):780-8 PMID: 20842059
  130. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
    Oncogene. 2010 May 13;29(19):2817-30 PMID: 20190816
  131. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
    Nat Genet. 2009 Jun;41(6):718-23 PMID: 19412175
  132. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
    Cancer Res. 1991 Sep 15;51(18):4865-70 PMID: 1654202
  133. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
    J Clin Oncol. 2012 Oct 1;30(28):3525-32 PMID: 22927533
  134. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
    JAMA. 2012 Mar 14;307(10):1062-71 PMID: 22416102
  135. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
    Int J Cancer. 1993 May 28;54(3):499-505 PMID: 8509225
  136. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.
    Oncogene. 2010 Jun 17;29(24):3583-92 PMID: 20383195
  137. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
    J Clin Oncol. 2009 Mar 1;27(7):1007-13 PMID: 19171716
  138. Promising therapeutic targets in neuroblastoma.
    Clin Cancer Res. 2012 May 15;18(10):2740-53 PMID: 22589483
  139. Neuroblastoma: biological insights into a clinical enigma.
    Nat Rev Cancer. 2003 Mar;3(3):203-16 PMID: 12612655
  140. Safety and immunologic effects of IL-15 administration in nonhuman primates.
    Blood. 2009 Sep 17;114(12):2417-26 PMID: 19605850
  141. Interleukin-15 biology and its therapeutic implications in cancer.
    Trends Pharmacol Sci. 2012 Jan;33(1):35-41 PMID: 22032984
  142. The International Neuroblastoma Pathology Classification (the Shimada system).
    Cancer. 1999 Jul 15;86(2):364-72 PMID: 10421273
  143. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Oncogene. 2013 Feb 21;32(8):1059-65 PMID: 22484425
  144. Systems genetics analysis of cancer susceptibility: from mouse models to humans.
    Nat Rev Genet. 2009 Sep;10(9):651-7 PMID: 19636343
  145. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Clin Cancer Res. 2011 Aug 1;17(15):5082-92 PMID: 21632861
  146. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
    EMBO J. 1997 Jun 2;16(11):2985-95 PMID: 9214616
  147. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
    Development. 2011 Nov;138(21):4699-708 PMID: 21989914
  148. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    N Engl J Med. 2005 Nov 24;353(21):2243-53 PMID: 16306521
  149. Analysis of early human neural crest development.
    Dev Biol. 2010 Aug 15;344(2):578-92 PMID: 20478300
  150. Catecholamine metabolism: a contemporary view with implications for physiology and medicine.
    Pharmacol Rev. 2004 Sep;56(3):331-49 PMID: 15317907
  151. Cancer immunotherapy comes of age.
    Nature. 2011 Dec 21;480(7378):480-9 PMID: 22193102
  152. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis.
    Cancer Res. 1998 May 15;58(10):2209-16 PMID: 9605768
  153. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Clin Cancer Res. 2011 Nov 1;17(21):6702-11 PMID: 21918174
  154. Germline PHOX2B mutation in hereditary neuroblastoma.
    Am J Hum Genet. 2004 Oct;75(4):727-30 PMID: 15338462
  155. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes.
    Cancer Res. 2000 Apr 1;60(7):1908-13 PMID: 10766179
  156. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
    Cancer Immunol Immunother. 2012 Dec;61(12):2261-71 PMID: 22678096
  157. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
    Clin Cancer Res. 2000 Jul;6(7):2653-60 PMID: 10914706
  158. Antibody therapy of cancer.
    Nat Rev Cancer. 2012 Mar 22;12(4):278-87 PMID: 22437872
  159. Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase.
    Br J Cancer. 2012 May 22;106(11):1807-15 PMID: 22531632
  160. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Mol Ther. 2007 Apr;15(4):825-33 PMID: 17299405
  161. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
    Clin Cancer Res. 2012 Feb 1;18(3):748-57 PMID: 22142829
  162. The blockade of immune checkpoints in cancer immunotherapy.
    Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PMID: 22437870
  163. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    N Engl J Med. 2010 Sep 30;363(14):1324-34 PMID: 20879881
  164. The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization.
    Curr Top Microbiol Immunol. 2010;345:1-20 PMID: 20517717
  165. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
    Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205 PMID: 22707078
  166. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    N Engl J Med. 1996 Jan 25;334(4):225-30 PMID: 8531999
  167. Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens.
    Int J Cancer. 1991 Jun 19;48(4):502-10 PMID: 1710608
  168. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
    J Clin Oncol. 1993 Aug;11(8):1466-77 PMID: 8336186
  169. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
    Cancer Res. 1984 Dec;44(12 Pt 1):5914-20 PMID: 6498849
  170. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Blood. 1989 May 15;73(7):1936-41 PMID: 2653466
  171. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
    N Engl J Med. 1996 Jan 25;334(4):231-8 PMID: 8532000
  172. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
    Cancer. 2005 Mar 15;103(6):1280-91 PMID: 15693021
  173. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
    Br J Cancer. 1993 May;67(5):933-8 PMID: 8494726
  174. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.
    Oncogene. 2008 Jan 17;27(4):469-76 PMID: 17637745
  175. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  176. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.
    J Clin Oncol. 2012 Feb 1;30(4):426-32 PMID: 22203761
  177. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.
    J Exp Med. 2004 May 3;199(9):1213-21 PMID: 15123743
  178. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.
    J Clin Oncol. 2011 Feb 1;29(4):441-8 PMID: 21149662
  179. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.
    Cancer Res. 2008 Apr 15;68(8):2599-609 PMID: 18413728
  180. Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function.
    Glycoconj J. 2011 May;28(3-4):137-47 PMID: 21519903
  181. Intra-tumour heterogeneity: a looking glass for cancer?
    Nat Rev Cancer. 2012 Apr 19;12(5):323-34 PMID: 22513401
  182. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    PLoS One. 2010 Oct 01;5(10): PMID: 20957039
  183. Childhood tumors of the nervous system as disorders of normal development.
    Curr Opin Pediatr. 2006 Dec;18(6):634-8 PMID: 17099362
  184. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
    PLoS One. 2012;7(11):e50062 PMID: 23185534
  185. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
    Cancer Res. 2007 Jan 1;67(1):32-40 PMID: 17210681
  186. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Clin Cancer Res. 2006 Nov 15;12(22):6772-80 PMID: 17121898
  187. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Oncogene. 2012 Nov 15;31(46):4859-67 PMID: 22266870
  188. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Cancer Res. 2005 Apr 15;65(8):3410-8 PMID: 15833876
  189. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.
    J Clin Oncol. 2006 Dec 20;24(36):5725-34 PMID: 17179106
  190. Recent advances in neuroblastoma.
    N Engl J Med. 2010 Jun 10;362(23):2202-11 PMID: 20558371
  191. The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma.
    J Pediatr Surg. 1995 Aug;30(8):1218-21 PMID: 7472988
  192. Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma.
    Oncogene. 2006 Jun 15;25(25):3501-8 PMID: 16449971
  193. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.
    Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5 PMID: 15314238
  194. Correlating telomerase activity levels with human neuroblastoma outcomes.
    Nat Med. 1995 Mar;1(3):249-55 PMID: 7585042
  195. ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction.
    Eur J Neurosci. 2009 Jan;29(2):275-86 PMID: 19200234
  196. Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.
    Front Oncol. 2012 Oct 12;2:141 PMID: 23091802
  197. Dose-intensity analysis and randomized trials.
    J Clin Oncol. 1991 Sep;9(9):1715-6 PMID: 1875228
  198. Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.
    Semin Cancer Biol. 2011 Oct;21(4):245-55 PMID: 21958944
  199. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.
    Am J Hum Genet. 2004 Apr;74(4):761-4 PMID: 15024693
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3526
Email
cheungn@mskcc.org
Published
2013-06-00
Pages
397-411
Language
English
Region
England
NLM ID
101124168
PMCID
PMC4386662
Subset
IM
Grants
NCI NIH HHS · CA161978 · United States
NEI NIH HHS · R01 EY018599 · United States
Howard Hughes Medical Institute · United States
NEI NIH HHS · R01 EY023619 · United States
NCI NIH HHS · R01 CA168875 · United States
NCI NIH HHS · R01 CA154754 · United States
NCI NIH HHS · P30 CA021765 · United States
NEI NIH HHS · EY018599 · United States
NEI NIH HHS · EY014867 · United States
NCI NIH HHS · CA154754 · United States
NCI NIH HHS · R21 CA161978 · United States
NCI NIH HHS · CA168875 · United States
NCI NIH HHS · CA21765 · United States
NEI NIH HHS · R01 EY014867 · United States
External Links
PubMed source DOI: 10.1038/nrc3526 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2